InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Investor Presentation (May 2015)
22 slides from InMed Pharmaceuticals's investor presentation, May 2015
Slide 1: Corporate Presentation
CORPORATE PRESENTATION May 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including statements concerning anticipated clinical development activities, the potential benefits of product candidates and anticipated market opportunities. All statements other than statements of historical fact ar
Slide 3: Our Vision
Our Vision: InMed was founded as a drug discovery and development company to offset and reduce the major challenges of modern biotech/pharma companies by addressing: Development Time Development Cost Risk of Clinical Failure • Novel network based algorithm • Virtual R & D model • Cannabinoid based t
Slide 4: InMed Overview
InMed Overview Our drug therapies have an accelerated development pathway from traditional Pharmaceuticals. InMed’s therapies are based on natural, non-synthetic cannabinoid s (reduced risk of side effects). Cannabis based medicines deliver “intelligent” drugs for multiple targets vs. traditio
Slide 5: Intelligent Drug Design Platform "IDP"
Intelligent Drug Design Platform “IDP” “IDP” is a proprietary bioinformatics tool employed to identify individual chemical compounds from the cannabis & non-cannabis plants, which can be targeted to develop therapies for specific diseases and conditions. The Advantages of our “IDP”: Generates new
Slide 6: Current Product Pipeline
Current Product Pipeline (Disease Focus) OCULAR DISEASES CTI-085 (GLAUCOMA) OCULAR ALLERGIES PAIN AND INFLAMMATION CTI-091 (CSIs) > OROFACIAL DERMATOLOGY INM-750 (EPIDERMOLYSIS BULLOSA)
Slide 7: About CTI-085 – Glaucoma Treatment
About CTI-085 – Glaucoma Treatment CTI-085 is being developed to prevent permanent vision damage caused by glaucoma. This novel cannabinoid based dual action ocular therapy not only reduces the elevated intra-ocular pressure (IOP) in the affected eyes, but also provides necessary neuroprotection for
Slide 8: Glaucoma Market Opportunity
Glaucoma Market Opportunity Pipeline of glaucoma treatments is relatively weak compared to other treatment areas Xalatan/Xalacom, Travatan and Lumigan accounted for 50% Pfizer’s Xalatan patent expired in 2011 2.7 million people in the United States suffer from glaucoma, a number that is expe
Slide 9: CTI-085 Reduces Intraocular Pressure in Mice
CTI-085 Reduces Intraocular Pressure in Mice Untreated (Left Eye) Treated (Right Eye) Retina Optic nerve Blood vessels Optical Coherence Tomography CTI-085 increased blood vessel diameter and reduced Intraocular Pressure after 30 minutes 10
Slide 10: CTI-085 Treatment + Delivery Vehicle
CTI-085 Treatment + Delivery Vehicle Problem: Glaucoma suffers exceptionally high rates of medication regimen non-compliance. A recent study showed that nearly one-half of the individuals who had filled a glaucoma prescription discontinued that topical therapy after only six months. Solution: InMed’
Slide 11: Arthritis Market Opportunity
Arthritis Market Opportunity Autoimmune disease that causes chronic joint inflammation. Also causes inflammation of the tissue around the joints and other organs in the body. 55 million people in North America alone suffer from arthritis. Arthritis is the leading cause of disability in the U
Slide 12: About CTI-091 – Arthritis/Inflammation Treatment
About CTI-091 – Arthritis/Inflammation Treatment Designed to relieve joint pain and swelling associated with arthritis and joint disease Proprietary mixture of cannabinoids and non-cannabis based active ingredients Proof-of-concept studies showed suppression of IL-6 by human macrophages Deve
Slide 13: Current & Proposed Target Areas
Current & Proposed Target Areas Ocular Diseases Inflammation/Pain • Glaucoma (CTI-085) • Arthritis (CTI-091) Primary Focus Orphan Disease Metabolic Disease • EBS- (INM-750) • Diabetes • Huntington’s • Obesity • Epilepsy Secondary Focus Dermatology Oncology • Skin squamous (SSC) & basal • Breast canc
Slide 14: R&D Activities in 2015-2016
R&D Activities in 2015-2016 Programs Milestones EBS- Orphan Disease • Conduct in vitro & in vivo studies with selected Inmed Compounds in Epidermolysis bullosa, Skin squamous (SSC) & basal cell carcinoma, Alopecia and Psoriasis Symptoms (Q1, 2015) • Proof of Concept- Human Surrogate Model (Q2, 2015)
Slide 15: Significantly Reduces the Drug Development Time Compared to Traditional Drug Development
Significantly Reduces the Drug Development Time Compared to Traditional Drug Development Health Canada Target Lead Lead Preclinical Clinical Trials Approval Identification Identification Optimization Studies (Phase I,II,II) (10-15 yrs.) Traditional Drug Development Pathway Phase I*, II & III Health
Slide 16: InMed's Accelerated Drug Development Process
InMed’s Accelerated Drug Development Process Impact of GW Pharma’s IDP bioinformatics Clinical Trials based platform (Sativex) Network Based Approach for Future Discovery 4- years to > 3000 Approval subjects (Bayer AG) in clinical trials Innovative Drug Delivery System No side effects or withdrawal
Slide 17: Major Pharmaceuticals Involved in Cannabinoid R & D and Commercialization
Major Pharmaceuticals Involved in Cannabinoid R & D and Commercialization 18
Slide 18: Valuation Relative to Peers
Valuation Relative to Peers ) US IS) NM F) CB LF : IM TC : TC ce (O : TC (O e .) ien (O nc Co a te m cie c iva oS ar S r (P Ph Bi is a ab us rb ed nn ne m M Ne Ca Zy Drug Discovery Platform In Propietary Delivery System Completed Pre-clinical Therapies 2 0 0 0 Pre-clinical Therapies
Slide 19: Key Personnel
Key Personnel Craig Schneider, B.A. – Chief Executive Officer 20 years of extensive experience in Capital market financing business development & strategic planning with public companies in Technology, Biotechnology and Resource sectors. Co-founder of Magnum Uranium, a TSX.V company which was pu
Slide 20: Team con't
TEAM con’t Peter Huang, M.Sc., BSc – Senior Bioinformatician Mr. Huang has over 17 years of experience Bioinformatics, software development and scientific research Mr. Huang’s experience spans multiple disciplines within computer and biological sciences, including plant mutation discoveries and
Slide 21: Capital Structure
Capital Structure CSE: IN Symbol: OTCQB: IMLFF Share I/O: 57.8Million Warrants: 2.7 Million Options: 13.7 Million Fully-Diluted: 76.8 Million Market Capitalization: $15.2 Million as of May 07, 2014 22
Slide 22: InMed Pharmaceuticals Inc.
Contact Information InMed Pharmaceuticals Inc. #350-409 Granville Street, Vancouver, BC Canada, V6C 1T2 Tel: 604.669.7207 Fax: 604.683.2506 www.inmedpharma.com 23
InMed Pharmaceuticals — Investor Presentation (May 2015) on 6ix